Results 201 to 210 of about 2,439,563 (414)

Cancer Prevalence Among Large Cohort of Individuals With Down Syndrome: Implications for Screening Guidelines. [PDF]

Cancer Med
Fitzpatrick V, Noah A, Rivelli A, Johnson R, Zak M, Espinosa J, Chicoine B.   +6 more
europepmc   +1 more source

Occurrence of Malignant Neoplasms in Patients with Atopic Dermatitis

, 1976
K Kaaber
openalex   +2 more sources

Malignant Head and Neck Neoplasm

, 2020
National Cancer Institute
openalex   +1 more source

Increased Risk of Neoplasms in Adult Patients Undergoing Interval Appendectomy [PDF]

, 2020
Jungtak Son, Yong Jun Park, Sung Ryol Lee, Hyung Ook Kim, Kyung Uk Jung   +4 more
openalex   +1 more source

Somatic mutations of calreticulin in myeloproliferative neoplasms.

New England Journal of Medicine, 2013
T. Klampfl, H. Gisslinger, A. Harutyunyan, Harini Nivarthi, E. Rumi, J. Milosevic, Nicole C. C. Them, T. Berg, B. Gisslinger, D. Pietra, Doris Chen, G. Vladimer, K. Bagienski, C. Milanesi, I. Casetti, Emanuela Sant'Antonio, V. Ferretti, C. Elena, Fiorella Schischlik, Ciara Cleary, M. Six, M. Schalling, Andreas Schönegger, C. Bock, L. Malcovati, C. Pascutto, G. Superti‐Furga, M. Cazzola, R. Kralovics   +28 more
semanticscholar   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Investigation of the Intensity of Thrombocytosis as a Potential Prognostic Indicator in Canine Malignant Neoplasms. [PDF]

Vet Med Int
Souto LG, Teng FS, Vieira SE, Takahira RK.   +3 more
europepmc   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Primary Cardiac Neoplasms: A 12-Year Institutional Experience at a National Cardiac Referral Center in Mexico. [PDF]

Cureus
Bernal Armenta A.
europepmc   +1 more source